Evidence map›Paper›PMID 9634537›Full record

ReviewAmerican journal of human genetics1998

Pharmacogenetics of cancer therapy: getting personal.

E Y Krynetski, W E Evans

Abstract readReview
In one paragraph

Review in American journal of human genetics, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Guideline
  2. Guideline
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Development and implementation of a pharmacist-managed clinical pharmacogenetics service.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2011
    Article
  10. Article
  11. Article
  12. Pharmacogenetics and diseases of the colon.Current opinion in gastroenterology · 2007
    Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

E Y KrynetskiSt. Jude Children's Research Hospital, Memphis, TN 38105, USA.
W E Evans

Funding

Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9M
PHARMACOGENOMICS OF CHILDHOOD LEUKEMIA (ALL)R37CA036401 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI EVANS, WILLIAM E · 1987 to 2014
$9.7M
TREATMENT OF RELAPSEP01CA020180 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI LOOK, A THOMAS · 1985 to 1997
–
NCI NIH HHS CA20180NCI NIH HHS CA21765NCI NIH HHS R37 CA36401
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

PharmacogeneticsAntineoplastic AgentsErythrocytesHumansMethyltransferasesNeoplasmsPolymorphism, GeneticAntineoplastic AgentsMethyltransferasesthiopurine methyltransferase

Identifiers

PMID9634537
PMCPMC1377260

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.